Mucolipidosis Type IV (MLIV) — Disease Characteristics Research Report

Executive summary

Mucolipidosis type IV (MLIV) is an ultra-rare, autosomal recessive lysosomal storage disorder caused by biallelic loss-of-function variants in MCOLN1, encoding the late endosome/lysosome cation channel TRPML1 (mucolipin-1). The disorder presents in infancy with global developmental delay and evolves as a hypomyelinating leukodystrophy with progressive motor impairment, severe visual loss (retinal degeneration with corneal clouding), and systemic manifestations including achlorhydria with hypergastrinemia. No approved disease-modifying therapies exist, but 2023–2024 research has accelerated biomarker discovery (blood proteomics) and preclinical-to-early clinical translation of AAV-mediated MCOLN1 gene replacement. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2, sangster2024abloodbrainbarrierpenetrant pages 1-2, NCT07398872 chunk 1)

1. Disease information

1.1 What is the disease?

MLIV is a pediatric-onset neurodevelopmental and neurodegenerative lysosomal storage disease. A typical clinical course includes early developmental delay in the first year of life, a psychomotor plateau around ~18–20 months, and later progressive motor decline with increased hypertonicity, progressive retinal degeneration/corneal clouding leading to blindness, and shortened lifespan into adulthood. (tobin2024plasmaproteomicsignature pages 1-3)

1.2 Key identifiers and synonyms

Table: This table summarizes core standardized identifiers and naming conventions for mucolipidosis type IV, including its MONDO and OMIM identifiers, causal gene, inheritance pattern, and common synonyms. It is useful as a compact reference for disease knowledge base curation.

Additional notes: Open Targets lists MLIV as MONDO_0009653 and supports a strong MCOLN1–MLIV association (target score ~0.85 with supporting literature). (OpenTargets Search: Mucolipidosis type IV-MCOLN1)

Common synonyms/alternative names: mucolipidosis IV; MLIV. (boudewyn2019currentconceptsin pages 3-5)

1.3 Evidence source types

Most disease definition and identifier mapping come from aggregated disease resources (MONDO/Open Targets) and review synthesis; mechanistic and translational claims rely on primary animal-model and patient-derived cell/tissue studies, plus ClinicalTrials.gov protocols for human research design. (OpenTargets Search: Mucolipidosis type IV-MCOLN1, sangster2024abloodbrainbarrierpenetrant pages 1-2, NCT07398872 chunk 1)

Not fully captured in retrieved evidence: ICD-10/ICD-11 and MeSH identifiers, and Orphanet ORPHA code (not available in the retrieved/citeable corpus for this run).

2. Etiology

2.1 Disease causal factors

Genetic cause (primary): biallelic pathogenic variants in MCOLN1 causing loss of TRPML1 function. (misko2021progressinelucidating pages 1-2, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

Mechanistic cause (cell biology): TRPML1 is a lysosomal/endolysosomal nonselective cation channel that mediates lysosomal release of divalent cations (notably Ca2+; also Zn2+/Fe2+ in broader TRPML1 biology) and regulates lysosomal trafficking and cellular homeostasis processes including endocytosis/exocytosis, lysosomal membrane fusion, and autophagy-related pathways. (tobin2024plasmaproteomicsignature pages 1-3, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

2.2 Risk factors

Inheritance: autosomal recessive; risk is driven by parental carrier status. (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

Founder effect / population risk: In Ashkenazi Jewish populations, two founder alleles account for ~95% of cases, with an estimated carrier frequency around ~1/100 and a predicted incidence of ~1:42,000 (as reported in a review synthesis). (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

2.3 Protective factors / gene–environment interactions

No disease-specific genetic protective alleles or robust gene–environment interactions were identified in the retrieved evidence set. MLIV is primarily a monogenic, high-penetrance lysosomal disorder. (misko2021progressinelucidating pages 1-2, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

3. Phenotypes

3.1 Core phenotype spectrum (with suggested HPO terms)

Below are key clinical features repeatedly described across reviews and translational studies.

1) Neurodevelopmental delay / intellectual disability (symptom/sign) - Typical onset: infancy (first year). (tobin2024plasmaproteomicsignature pages 1-3, NCT00015782 chunk 1) - Suggested HPO: Global developmental delay (HP:0001263); Intellectual disability (HP:0001249); Delayed speech and language development (HP:0000750).

2) Motor impairment with progressive decline / spasticity-hypertonia - Course: plateau in toddler years and later progressive worsening with hypertonicity. (tobin2024plasmaproteomicsignature pages 1-3) - Suggested HPO: Motor delay (HP:0001270); Spasticity (HP:0001257); Hypertonia (HP:0001276).

3) Hypomyelinating leukodystrophy / white-matter abnormalities - MLIV is characterized as a hypomyelinating leukodystrophy with brain iron accumulation in mechanistic reviews, and white-matter/corpus callosum abnormalities are repeatedly noted. (misko2021progressinelucidating pages 1-2) - Suggested HPO: Hypomyelination (HP:0011400); Abnormality of cerebral white matter (HP:0002500); Corpus callosum hypoplasia (HP:0002079).

4) Progressive visual impairment leading to blindness - Features: retinal degeneration plus corneal clouding; progressive to blindness. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2) - Suggested HPO: Visual impairment (HP:0000505); Retinal dystrophy (HP:0000556); Corneal opacity (HP:0007957); Blindness (HP:0000618).

5) Gastrointestinal/systemic hallmark: achlorhydria with hypergastrinemia - High gastrin is repeatedly cited as a non-CNS hallmark and used diagnostically. (tobin2024plasmaproteomicsignature pages 1-3, boudewyn2019currentconceptsin pages 3-5) - Suggested HPO: Increased circulating gastrin level (HP:0003075); Achlorhydria (HP:0003088).

3.2 Frequency/severity and QoL impact

• Quantitative phenotype frequencies were not consistently available in the retrieved primary evidence. However, the literature consistently emphasizes severe neurodevelopmental disability and progressive visual loss as major determinants of lifelong dependency and reduced quality of life. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2)

4. Genetic / molecular information

4.1 Causal gene

• MCOLN1 (human), encoding TRPML1/mucolipin-1. (boudewyn2019currentconceptsin pages 3-5, misko2021progressinelucidating pages 1-2)

4.2 Pathogenic variant classes and founder variants

• Variant spectrum includes splice, deletion, and diverse additional alleles; one review reports ~35 pathogenic/likely pathogenic MLIV-related variants described at the time. (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)
• Founder alleles in Ashkenazi Jewish populations explain most cases; one review summarized two common founder variants explaining ~95% of cases, and provides carrier frequency and predicted incidence estimates. (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

4.3 Functional consequences

• MLIV pathogenic variants are typically loss-of-function and reduce/ablate TRPML1 channel function, disrupting lysosomal ion homeostasis and downstream processes such as Ca2+-dependent trafficking and autophagy. (tobin2024plasmaproteomicsignature pages 1-3, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No MLIV-specific modifier-gene or epigenetic signatures were identified in the retrieved citeable evidence. Chromosomal abnormalities are not typical for this Mendelian disorder. (misko2021progressinelucidating pages 1-2, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

5. Environmental information

MLIV is a monogenic lysosomal channelopathy; no specific environmental, lifestyle, toxic, or infectious causal contributors were identified in the retrieved evidence. (misko2021progressinelucidating pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (upstream → downstream)

1) MCOLN1 loss-of-function → 2) TRPML1 channel dysfunction on lysosomes/endosomes → 3) impaired lysosomal ionic homeostasis and Ca2+-dependent membrane fusion/trafficking plus dysregulated autophagy and lysosomal biogenesis programs → 4) storage-material accumulation and cell-type-specific stress responses (glial activation, hypomyelination) → 5) CNS dysfunction (developmental delay, progressive motor impairment), retinal degeneration/corneal disease, and systemic manifestations such as achlorhydria/hypergastrinemia. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

6.2 Cellular processes and pathways implicated

• Lysosomal trafficking and fusion/exocytosis and autophagy are repeatedly emphasized as TRPML1-regulated processes. (tobin2024plasmaproteomicsignature pages 1-3, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)
• CNS disease is described as hypomyelinating leukodystrophy, suggesting oligodendrocyte/myelin biology is affected downstream of lysosomal dysfunction. (misko2021progressinelucidating pages 1-2)

Suggested GO biological process terms (examples): - Autophagy (GO:0006914) - Lysosome organization (GO:0007040) - Endosome to lysosome transport (GO:0008333) - Calcium ion transport (GO:0006816) - Myelination (GO:0042552)

Suggested GO cellular component terms (subcellular localization): - Lysosome (GO:0005764); Late endosome (GO:0005770)

6.3 Cell types (CL) and tissue mechanisms

• The CNS predominance of MLIV implies involvement of neurons, oligodendrocytes, astrocytes, and microglia in disease pathways; MLIV animal model studies explicitly analyze neurologic outcomes and glial activation markers, consistent with neuroinflammatory/astroglial involvement downstream of lysosomal dysfunction. (sangster2023abloodbrainbarrierpenetrant pages 22-30, sangster2024abloodbrainbarrierpenetrant pages 3-4)

Suggested CL terms (examples): - Neuron (CL:0000540); Oligodendrocyte (CL:0000128); Astrocyte (CL:0000127); Microglial cell (CL:0000129)

6.4 Molecular profiling and biomarkers (2024 focus)

Human plasma proteomics (biomarker discovery): A 2024 preprint used SomaScan aptamer profiling (~7,322 proteins) in 18 MLIV patients vs 37 controls, identifying 1,961 differentially expressed proteins and 45 proteins overlapping with MLIV mouse brain signatures (upregulated lysosomal proteins and downregulated myelination-associated proteins), proposing candidate blood biomarker panels for monitoring disease and therapy response. (tobin2024plasmaproteomicsignature pages 1-3)

A later section of the same preprint emphasizes overlap between human plasma and mouse brain changes and highlights candidate proteins/pathways linked to neuronal/lysosomal biology while noting discovery-stage limitations (small cohort, cross-sectional design). (tobin2024plasmaproteomicsignature pages 17-19)

7. Anatomical structures affected

7.1 Organ level (UBERON suggestions)

• Brain / CNS (primary): neurodevelopmental delay, leukodystrophy/hypomyelination. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2)
• UBERON: brain (UBERON:0000955); cerebral white matter (UBERON:0006102)
• Eye (primary): retinal degeneration and corneal clouding. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2)
• UBERON: retina (UBERON:0000966); cornea (UBERON:0000964)
• Stomach (systemic hallmark): achlorhydria/hypergastrinemia. (tobin2024plasmaproteomicsignature pages 1-3, boudewyn2019currentconceptsin pages 3-5)
• UBERON: stomach (UBERON:0000945)

7.2 Subcellular level

• Primary compartment: lysosome/endolysosome. (tobin2024plasmaproteomicsignature pages 1-3, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

8. Temporal development (natural history)

• Onset: typically in the first year of life, including delayed motor development and/or corneal clouding. (tobin2024plasmaproteomicsignature pages 1-3, NCT00015782 chunk 1)
• Course: psychomotor plateau in late infancy/toddler period (~18–20 months) followed by progressive motor decline and progressive visual loss. (tobin2024plasmaproteomicsignature pages 1-3)
• Variability: natural history protocols report some patients deteriorate while others remain stable, supporting heterogeneous progression (potentially genotype-related). (NCT00015782 chunk 1)

9. Inheritance and population

9.1 Inheritance

• Autosomal recessive. (misko2021progressinelucidating pages 1-2, jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

9.2 Population genetics / founder effects

• Ashkenazi Jewish founder alleles and carrier frequency/incidence estimates are reported in review synthesis (carrier frequency ~1/100; predicted incidence ~1:42,000). (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3)

9.3 Prevalence/incidence (general)

Robust population-level prevalence outside founder populations was not identified in the retrieved citeable corpus. An older natural history protocol noted “more than 80 diagnosed patients” at that time (a historical count rather than a modern prevalence estimate). (NCT00015782 chunk 1)

10. Diagnostics

10.1 Clinical and laboratory clues

• A distinctive systemic clue is achlorhydria with elevated plasma gastrin, which is described as diagnostically helpful in MLIV. (boudewyn2019currentconceptsin pages 3-5, NCT05782387 chunk 1)
• Ophthalmologic findings (corneal clouding, retinal degeneration) are prominent and may aid recognition. (tobin2024plasmaproteomicsignature pages 1-3, misko2021progressinelucidating pages 1-2)

10.2 Genetic testing

• Diagnosis is confirmed by identifying biallelic pathogenic variants in MCOLN1; clinical studies and natural history protocols use genetic confirmation as an inclusion criterion. (NCT05782387 chunk 1, NCT07398872 chunk 1)

10.3 Imaging and neurophysiology

• Natural history study design includes longitudinal analysis of brain MRI abnormalities and EEG patterns as candidate progression biomarkers. (NCT05782387 chunk 1)

11. Outcome / prognosis

• MLIV is associated with progressive neurologic disability and shortened lifespan in general descriptions; specific survival curves or mortality rates were not available in the retrieved evidence set. (tobin2024plasmaproteomicsignature pages 1-3, boudewyn2019currentconceptsin pages 3-5)

12. Treatment

12.1 Standard of care (current real-world implementation)

• No disease-modifying therapy is established; management is primarily supportive (multidisciplinary care for neurodevelopmental disability, spasticity, feeding issues, and ophthalmologic complications). Supportive-only framing is explicitly stated in recent biomarker-focused work. (tobin2024plasmaproteomicsignature pages 1-3)

12.2 Advanced therapeutics and experimental treatments

12.2.1 AAV gene therapy (preclinical 2023–2024)

A major 2024 advance is systemic, blood–brain barrier-penetrant AAV delivery of MCOLN1 in symptomatic MLIV mice.

• Vector/capsid: self-complementary MCOLN1 packaged in engineered capsid AAV.CPP.16 (CPP16); chosen for cross-species CNS transduction. (sangster2024abloodbrainbarrierpenetrant pages 2-3)
• Route: single intravenous (tail vein) administration in symptomatic adult/young-adult Mcoln1−/− mice. (sangster2024abloodbrainbarrierpenetrant pages 1-2, sangster2024abloodbrainbarrierpenetrant pages 3-4)
• Dose dependence: doses tested included 5×10^11 vg/mouse and 1×10^12 vg/mouse. (sangster2024abloodbrainbarrierpenetrant pages 2-3, sangster2024abloodbrainbarrierpenetrant pages 3-4)
• Key outcomes: dose-dependent restoration of neuromotor function, delayed paralysis, correction of brain pathology; high dose prevented paralysis through the study period and extended survival relative to controls; retinal transgene transcripts were detected but retinal thickness did not recover in treated mice with established degeneration. (sangster2024abloodbrainbarrierpenetrant pages 1-2, sangster2024abloodbrainbarrierpenetrant pages 3-4)
• Translational interpretation: authors conclude systemic CPP16-MCOLN1 “suggest[s] a new AAV-based systemic gene replacement therapy… that could be translated into clinical studies” and emphasize CPP16’s improved CNS transduction vs AAV9 as a translational advantage. (sangster2024abloodbrainbarrierpenetrant pages 1-2, sangster2024abloodbrainbarrierpenetrant pages 2-3)

Visual evidence (study design + behavioral rescue): key figures summarizing design and behavioral outcomes (vertical activity, rotarod, paralysis curves) were retrieved from the 2024 paper. (sangster2024abloodbrainbarrierpenetrant media 9c706bf6, sangster2024abloodbrainbarrierpenetrant media d7571dbf)

MAXO suggestions: gene replacement therapy (MAXO:0001175, “gene therapy”); intrathecal/intracerebroventricular administration (MAXO term may vary by ontology version; conceptually ‘intrathecal drug administration’).

12.2.2 Human interventional trial (2026 start; early clinical translation)

NCT07398872 (Phase 1) evaluates AAV9.hMCOLN1co in pediatric MLIV. - Design: interventional, single-group/open-label, single-arm; estimated enrollment 1. (NCT07398872 chunk 1) - Route/dose: single intrathecal infusion, 10 mL at 2×10^13 vg/mL (total 2×10^14 vg). (NCT07398872 chunk 1) - Key eligibility: ages 1.5–8 years, confirmed MCOLN1-caused MLIV; exclusions include contraindications to intrathecal therapy, severe scoliosis (Cobb ≥50°), major comorbid disease, and anti-AAV9 antibody titer >1:50 (with possible retest). (NCT07398872 chunk 1) - Primary endpoint: incidence/severity of AEs/SAEs (CTCAE v5.0), follow-up averaging ~5 years. (NCT07398872 chunk 1) - Dates: start 2026-01-13; primary completion estimated 2027-01-20; study completion estimated 2031-01-20. (NCT07398872 chunk 1)

12.2.3 Natural history and endpoint development (2023–2028)

NCT05782387 (MGH; 2023 start) is a retrospective natural history study (planned n≈50) designed to define milestone attainment/loss ages, quantify gross motor function trajectories (GMFCS and MLIV-specific scale), quantify visual decline rate, and analyze EEG/MRI biomarkers; it also aims to provide baseline lab values relevant to monitoring gene therapy safety. (NCT05782387 chunk 1)

12.3 Biomarkers supporting treatment development (2024)

Plasma proteomics provides a route to objective, minimally invasive biomarkers for interventional trials, including gene therapy, by identifying disease-associated protein signatures and cross-species overlap with MLIV mouse brain. (tobin2024plasmaproteomicsignature pages 1-3, tobin2024plasmaproteomicsignature pages 17-19)

13. Prevention

Primary prevention is not applicable in the conventional sense for monogenic MLIV; prevention focuses on genetic counseling and carrier testing (particularly in higher-risk populations with founder variants) and reproductive planning options.

Secondary/tertiary prevention: early recognition and supportive interventions (feeding management, rehabilitation, ophthalmologic monitoring) and enrollment into natural history studies to optimize timing and endpoints for emerging gene therapies. (NCT05782387 chunk 1, NCT07398872 chunk 1)

14. Other species / natural disease

No naturally occurring veterinary MLIV analogs were identified in the retrieved citeable corpus.

15. Model organisms

15.1 Mouse model

The Mcoln1−/− mouse is repeatedly used as a preclinical MLIV model and is leveraged for mechanistic studies, biomarker alignment, and gene therapy testing, including systemic BBB-penetrant AAV delivery of MCOLN1 with neuromotor rescue and prevention of paralysis. (sangster2024abloodbrainbarrierpenetrant pages 1-2, sangster2024abloodbrainbarrierpenetrant pages 3-4)

15.2 Translational applications

• Mechanism dissection: assessing CNS pathology and downstream glial/lysosomal markers.
• Therapeutic development: vector selection, dose-ranging, biodistribution, behavioral endpoints (rotarod, open-field, paralysis), and correlation of brain expression with functional outcomes. (sangster2023abloodbrainbarrierpenetrant pages 22-30, sangster2024abloodbrainbarrierpenetrant pages 3-4)

Expert opinion / analysis (authoritative perspectives in retrieved sources)

• Reviews and translational reports consistently frame MLIV as a high unmet-need disorder driven by lysosomal TRPML1 dysfunction and emphasize the importance of natural history and biomarkers to enable feasible interventional trials. (boudewyn2019currentconceptsin pages 3-5, misko2021progressinelucidating pages 1-2, NCT05782387 chunk 1)
• 2024 gene-therapy work argues that cross-species BBB-penetrant AAV capsids (e.g., CPP16) are critical for clinical translation because AAV platforms can differ substantially in CNS transduction across species; CPP16’s reported enhanced CNS transduction in mice and non-human primates underpins this rationale. (sangster2024abloodbrainbarrierpenetrant pages 2-3)

Key URLs (access points)

• Open Targets MCOLN1–MLIV association (MONDO_0009653): https://platform.opentargets.org/ (OpenTargets Search: Mucolipidosis type IV-MCOLN1)
• Sangster et al., 2024 (Molecular Therapy – Methods & Clinical Development): https://doi.org/10.1016/j.omtm.2024.101269 (published 2024-06) (sangster2024abloodbrainbarrierpenetrant pages 1-2)
• Tobin et al., 2024 (medRxiv preprint; plasma proteomics): https://doi.org/10.1101/2024.07.29.24311030 (posted 2024-07) (tobin2024plasmaproteomicsignature pages 1-3)
• ClinicalTrials.gov NCT07398872: https://clinicaltrials.gov/study/NCT07398872 (start 2026-01-13) (NCT07398872 chunk 1)
• ClinicalTrials.gov NCT05782387: https://clinicaltrials.gov/study/NCT05782387 (start 2023-03-15) (NCT05782387 chunk 1)

Data gaps (explicit)

• ICD-10/ICD-11, MeSH, and Orphanet ORPHA identifiers were not available in the retrieved citeable documents for this run.
• Robust global prevalence estimates, phenotype frequency tables, and survival statistics were not available in the retrieved evidence set.
• Modifier genes, epigenetic signatures, and gene–environment interactions specific to MLIV were not identified in the retrieved evidence set.

References

1. (tobin2024plasmaproteomicsignature pages 1-3): Brendan Tobin, Albert Misko, Victoria Miller-Browne, Madison Sangster, Yulia Grishchuk, and Levi B. Wood. Plasma proteomic signature of mucolipidosis type iv. MedRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.29.24311030, doi:10.1101/2024.07.29.24311030. This article has 0 citations.

2. (misko2021progressinelucidating pages 1-2): Albert Misko, Levi Wood, Kirill Kiselyov, Susan Slaugenhaupt, and Yulia Grishchuk. Progress in elucidating pathophysiology of mucolipidosis iv. Jun 2021. URL: https://doi.org/10.1016/j.neulet.2021.135944, doi:10.1016/j.neulet.2021.135944. This article has 29 citations and is from a peer-reviewed journal.

3. (sangster2024abloodbrainbarrierpenetrant pages 1-2): Madison L. Sangster, Martha M. Bishop, Yizheng Yao, Jessica F. Feitor, Sanjid Shahriar, Maxwell E. Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain barrier-penetrant aav gene therapy improves neurological function in symptomatic mucolipidosis iv mice. Molecular Therapy - Methods & Clinical Development, 32:101269, Jun 2024. URL: https://doi.org/10.1016/j.omtm.2024.101269, doi:10.1016/j.omtm.2024.101269. This article has 11 citations.

4. (NCT07398872 chunk 1): Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV. The Children's Hospital of Zhejiang University School of Medicine. 2026. ClinicalTrials.gov Identifier: NCT07398872

5. (OpenTargets Search: Mucolipidosis type IV-MCOLN1): Open Targets Query (Mucolipidosis type IV-MCOLN1, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (boudewyn2019currentconceptsin pages 3-5): Lauren C. Boudewyn and Steven U. Walkley. Current concepts in the neuropathogenesis of mucolipidosis type iv. Journal of Neurochemistry, 148:669-689, Aug 2019. URL: https://doi.org/10.1111/jnc.14462, doi:10.1111/jnc.14462. This article has 57 citations and is from a domain leading peer-reviewed journal.

7. (jezelastanek2020neuropathophysiologygeneticprofile pages 1-3): Aleksandra Jezela-Stanek, Elżbieta Ciara, and Karolina M. Stepien. Neuropathophysiology, genetic profile, and clinical manifestation of mucolipidosis iv—a review and case series. International Journal of Molecular Sciences, 21:4564, Jun 2020. URL: https://doi.org/10.3390/ijms21124564, doi:10.3390/ijms21124564. This article has 23 citations.

8. (NCT00015782 chunk 1): The Natural History and Pathogenesis of Mucolipidosis Type IV. National Institute of Neurological Disorders and Stroke (NINDS). 2001. ClinicalTrials.gov Identifier: NCT00015782

9. (sangster2023abloodbrainbarrierpenetrant pages 22-30): Madison Sangster, Martha Bishop, Yizheng Yao, Jessica Feitor, Sanjid Shahriar, Maxwell Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain-barrier penetrant aav gene therapy rescues neurological deficits in mucolipidosis iv mice. bioRxiv, Nov 2023. URL: https://doi.org/10.1101/2023.11.03.565568, doi:10.1101/2023.11.03.565568. This article has 1 citations.

10. (sangster2024abloodbrainbarrierpenetrant pages 3-4): Madison L. Sangster, Martha M. Bishop, Yizheng Yao, Jessica F. Feitor, Sanjid Shahriar, Maxwell E. Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain barrier-penetrant aav gene therapy improves neurological function in symptomatic mucolipidosis iv mice. Molecular Therapy - Methods & Clinical Development, 32:101269, Jun 2024. URL: https://doi.org/10.1016/j.omtm.2024.101269, doi:10.1016/j.omtm.2024.101269. This article has 11 citations.

11. (tobin2024plasmaproteomicsignature pages 17-19): Brendan Tobin, Albert Misko, Victoria Miller-Browne, Madison Sangster, Yulia Grishchuk, and Levi B. Wood. Plasma proteomic signature of mucolipidosis type iv. MedRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.29.24311030, doi:10.1101/2024.07.29.24311030. This article has 0 citations.

12. (NCT05782387 chunk 1): Patricia Musolino, MD PhD. Mucolipidosis Type IV Natural History Study. Massachusetts General Hospital. 2023. ClinicalTrials.gov Identifier: NCT05782387

13. (sangster2024abloodbrainbarrierpenetrant pages 2-3): Madison L. Sangster, Martha M. Bishop, Yizheng Yao, Jessica F. Feitor, Sanjid Shahriar, Maxwell E. Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain barrier-penetrant aav gene therapy improves neurological function in symptomatic mucolipidosis iv mice. Molecular Therapy - Methods & Clinical Development, 32:101269, Jun 2024. URL: https://doi.org/10.1016/j.omtm.2024.101269, doi:10.1016/j.omtm.2024.101269. This article has 11 citations.

14. (sangster2024abloodbrainbarrierpenetrant media 9c706bf6): Madison L. Sangster, Martha M. Bishop, Yizheng Yao, Jessica F. Feitor, Sanjid Shahriar, Maxwell E. Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain barrier-penetrant aav gene therapy improves neurological function in symptomatic mucolipidosis iv mice. Molecular Therapy - Methods & Clinical Development, 32:101269, Jun 2024. URL: https://doi.org/10.1016/j.omtm.2024.101269, doi:10.1016/j.omtm.2024.101269. This article has 11 citations.

15. (sangster2024abloodbrainbarrierpenetrant media d7571dbf): Madison L. Sangster, Martha M. Bishop, Yizheng Yao, Jessica F. Feitor, Sanjid Shahriar, Maxwell E. Miller, Anil K. Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. A blood-brain barrier-penetrant aav gene therapy improves neurological function in symptomatic mucolipidosis iv mice. Molecular Therapy - Methods & Clinical Development, 32:101269, Jun 2024. URL: https://doi.org/10.1016/j.omtm.2024.101269, doi:10.1016/j.omtm.2024.101269. This article has 11 citations.

Artifacts

• Edison artifact artifact-00